Sign In
Buy EXEL
$56.70
+0.700 (+1.25%)
At Close: Aug 05, 2026
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term
10:55am, Wednesday, 04'th Jun 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Looking for Earnings Beat? Buy These 5 Top-Ranked Stocks
08:01am, Wednesday, 04'th Jun 2025
Top-ranked stocks Urban Outfitters (URBN), Tenet Healthcare (THC), Five9 (FIVN), Marqeta (MQ) and Exelixis (EXEL) are likely to beat on the bottom line in their upcoming releases.
Here's Why Exelixis (EXEL) is a Strong Growth Stock
10:51am, Monday, 02'nd Jun 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Top 4 Value Stocks With Impressive PEG Ratios to Buy Now
10:36am, Friday, 30'th May 2025
Here are the four discounted PEG-based value stocks that qualify our screening criteria- URBN, XRAY, LTM and EXEL.
2 Top Stocks to Buy With Less Than $100
08:00am, Friday, 30'th May 2025
When investing on a budget, buying fractional shares of top companies is one option. Another is to find stocks with relatively affordable price tags per share.
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
10:46am, Wednesday, 28'th May 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Exelixis (EXEL) Upgraded to Buy: What Does It Mean for the Stock?
02:58pm, Friday, 23'rd May 2025
Exelixis (EXEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Earnings Estimates Moving Higher for Exelixis (EXEL): Time to Buy?
02:58pm, Friday, 23'rd May 2025
Exelixis (EXEL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
3 Reasons Why Growth Investors Shouldn't Overlook Exelixis (EXEL)
02:58pm, Friday, 23'rd May 2025
Exelixis (EXEL) possesses solid growth attributes, which could help it handily outperform the market.
EXEL vs. ARGX: Which Stock Is the Better Value Option?
12:41pm, Friday, 23'rd May 2025
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and argenex SE (ARGX). But which of these two stocks offers value investors a better bang for
EXEL Reports Superior Efficacy Data From Kidney Cancer Study Cohort
11:01am, Friday, 23'rd May 2025
Exelixis' zanzalintinib/Opdivo combo shows superior efficacy for treating kidney cancer in an expansion cohort of the phase Ib/II STELLAR-002 study.
Product Performance, Big Money Lift Exelixis
06:25am, Friday, 23'rd May 2025
Shares of Exelixis, Inc. (EXEL), an oncology-focused biopharmaceutical firm, boosted by Big Money inflows.
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from an expansion cohort of the phase 1b/2 STELLAR-002 trial evaluating zanzalintinib in combination with either
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May and June
04:05pm, Thursday, 22'nd May 2025
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in May and June: TD Cow
Exelixis (EXEL) is a Great Momentum Stock: Should You Buy?
01:06pm, Monday, 19'th May 2025
Does Exelixis (EXEL) have what it takes to be a top stock pick for momentum investors? Let's find out.
